



IN THE CLAIMS

RECEIVED


DEC 05 2002

TECH CENTER 1600/2900

Please cancel claims 1-8, and 10.

Please amend the claims as follows:

9. (amended) A method of treating a neoplastic condition or toxicity ^{in a subject} associated with an alteration in sphingolipid metabolism ^{in a subject in need thereof} comprising administering ^{to said subject} an effective amount of a fumonisin analog of the formula:



Where is support for clm. 39?
this? there is nothing in clm. 39 which says "fumonisin analog"

C1 wherein the spacer group is selected from the group consisting of alkyl (straight chain or branched, C₁ - C₂₀), hydroxyalkyl (straight chain or branched, C₁ - C₂₀) or dihydroxyalkyl (straight chain or branched, C₁ - C₂₀); Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O), CO₂, C(O)NH, and C(O)NQ, wherein Q is an alkyl (straight chain or branched, C₁ - C₆); W is selected from the group consisting of no substituent, H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo), C(O)(CH₂)_nCO₂H (where n= 1 - 6), C(O) (CH₂)_n CW'₂ CO₂ H, where W' is selected independently from H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo), and (CH₂)_n CO₂ H, wherein n= 1 - 6; X is selected from the group consisting of H, methyl, CH₂ OH (and esters thereof), CH₂ NQ'₂ (where Q' is selected independently from H, alkyl (straight chain or branched, C₁ - C₂₀), and acyl (C(O)Q" where Q" is an alkyl, straight chain or branched, C₁ - C₂₀)); and V and Y are independently selected from the group consisting of H or OH (and esters thereof).

C2 11. (amended) The method of Claim 9, wherein ^{the subject has} Neimann-Picks syndrome or Tay-Sachs disease ~~is treated~~.